Search for a trial

Highly restrictive vs normal red blood cell transfusion strategy in anemic critically ill patients - A feasibility trial

The primary objective is feasibility of a prospective randomized trial, to investigate whether a more restrictive RBC transfusion strategy of 5.0 g/dL (3.1 mmol/L) is non-inferior compared to the current transfusion threshold of 7.0 g/dL (4.3mmol/L…

The change of red blood cell properties and platelet function over time during extracorporeal life support

Objective: Primary objective: Red blood cell aggregation and elongation (deformability) assessed by a laser assisted optical rotational cell analyzer (LORCA) on days 1-3, and within 24 hours after weaning of ECLS. Secondary objectives are red blood…

A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency

CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…

Apheresis based treatment of sepsis

To determine the efficacy of a filter-based depletion of RBC-pathogen complexes by a single apheresis tretatment in patients with sepsis.

Effect of the number of epoetin alpha injections on the hemoglobin level of anaemic patients eligible for elective orthopedic surgery

Primary aim:- What is the increase in hemoglobin concentration between epoetin alpha injection number three and four in patients awaiting orthopedic surgery?Secondary aim:- What is de increase in hemoglobin concentration between epoetin alpha…

A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

The primary objectives of this study are to establish the efficacy and safety of APL-2 compared to eculizumab in patients with PNH who continue to have Hb levels <10.5 g/dL despite treatment with eculizumab.